(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.05%.
Tvardi Therapeutics's earnings in 2026 is -$26,660,000.On average, 11 Wall Street analysts forecast TVRD's earnings for 2026 to be -$28,624,384, with the lowest TVRD earnings forecast at -$39,550,292, and the highest TVRD earnings forecast at -$7,015,780. On average, 11 Wall Street analysts forecast TVRD's earnings for 2027 to be -$29,774,971, with the lowest TVRD earnings forecast at -$59,194,477, and the highest TVRD earnings forecast at -$7,156,096.
In 2028, TVRD is forecast to generate -$38,127,091 in earnings, with the lowest earnings forecast at -$81,719,809 and the highest earnings forecast at -$1,824,103.